ArticleScientific reports2018
DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2.Scientific reports · 2026Article
- Alphavirus replicons encoding IFN-γ enhance cancer virotherapy by overcoming macrophage-mediated suppression.iScience · 2025Article
- Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization.Journal of virology · 2024Article
- Review
- Application of DNA Replicons in Gene Therapy and Vaccine Development.Pharmaceutics · 2023Review
- Viruses as tools in gene therapy, vaccine development, and cancer treatment.Archives of virology · 2022Review
- The nano delivery systems and applications of mRNA.European journal of medicinal chemistry · 2022Review
- Extracellular Vesicles and Their Use as Vehicles of Immunogens.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.Frontiers in immunology · 2022Article
- Facile method for delivering chikungunya viral replicons into mosquitoes and mammalian cells.Scientific reports · 2021Article
- COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.Journal of virology · 2021Article
- DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.Scientific reports · 2021Article
- Self-Amplifying RNA Viruses as RNA Vaccines.International journal of molecular sciences · 2020Review
- Viral replicons as valuable tools for drug discovery.Drug discovery today · 2020Review
- Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.Journal of virology · 2019Article
- In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice.Vaccines · 2019Article
- Plasmid DNA-based Alphavirus Vaccines.Vaccines · 2019Review
- Review
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Human vaccines & immunotherapeutics · 2019Review
- Self-Replicating RNA Viruses for RNA Therapeutics.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are currently no licensed therapeutic treatment or preventive vaccines against Ebolavirus disease, and the 2013-2016 West African outbreak of Ebolavirus disease spread rapidly and resulted in almost 30,000 cases and more than 11,000 deaths. However, the devastating outbreak has spurred the development of novel Ebolavirus vaccines. Here, we demonstrate that alphavirus-based DNA-launched self-replicating RNA replicon vaccines (DREP) encoding either the glycoprotein (GP) gene or co-expressing the GP and VP40 genes of Sudan or Zaire Ebolavirus are immunogenic in mice inducing both binding and neutralizing antibodies as well as CD8 T cell responses. In addition, antibodies were cross-reactive against another Ebolavirus, although the specificity was higher for the vaccination antigen. DREP vaccines were more immunogenic than recombinant MVA vaccines expressing the same Ebolavirus antigens. However, a DREP prime followed by an MVA boost immunization regimen improved vaccine immunogenicity as compared to DREP and MVA homologous prime-boost immunizations. Moreover, we show that a bivalent approach targeting both Sudan and Zaire Ebolavirus can be employed without significant loss of immunity. This opens for further investigation of a pan-Ebolavirus or even a pan-filovirus vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.